Home / Stocks / Ambalal Sarabhai Ent L
AMBALALSA

Ambalal Sarabhai Ent L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹41.09

Change

-0.18 (-0.44%)

Open

₹42.85

Prev. Close

₹41.27

Day High

₹42.85

Day Low

₹40.5

Volume Analysis

Traded

24,559

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (15.9%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹44.81 ₹43.83 ₹42.46 ₹41.48 ₹40.11 ₹39.13 ₹37.76
Fibonacci ₹43.83 ₹42.93 ₹42.38 ₹41.48 ₹40.58 ₹40.03 ₹39.13
Camarilla ₹41.74 ₹41.52 ₹41.31 ₹41.48 ₹40.87 ₹40.66 ₹40.44

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+6.09%

1 Month

-6.63%

3 Months

+25.47%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹32.87

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.62%

Net margin 6.8% × asset turnover 0.72x × equity multiplier 1.76x

Company Overview

Sector

Healthcare

Market Cap

₹316 Cr

P/E (TTM)

22.2

ROE

12.4%

Book Value

₹20.7

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Ambalal Sarabhai Ent L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Financial Strength (96/100), while Liquidity (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising. Strong 3-year EPS growth (15.9%).

TopFund Score — Fundamentals Quality

53/100 — Average

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

96

Growth

33

Valuation

54

Cash Flow

61

Corporate Governance

52

Momentum

68

Institutional Ownership

30

Business Quality

51

Risk & Volatility

62

Liquidity

0

From Screener.in

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of 4.35% over past five years.
  • −Promoter holding is low: 31.4%
  • −Tax rate seems low

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

We hereby submit Newspaper publication. Kindly take the same on your records.

Q1 FY27 consolidated snapshot: income Rs 45.59 crore, EBITDA Rs 6.57 crore, PBT Rs 4.68 crore.

Company clarifies no unpublished price-sensitive information; share price movement is market-driven.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 36 40 43 54 41 45 46 65 40 44 52 65 44
Expenses + 40 39 41 50 40 42 47 60 39 44 48 60 39
Operating Profit -4 1 3 5 0 3 -1 5 1 0 4 6 5
OPM % -11.0% 2.52% 5.87% 8.56% 1.15% 5.68% -1.52% 8.18% 3.62% 0.81% 7.85% 8.7% 10.45%
Other Income + 1 3 2 5 2 3 6 -5 8 2 2 3 2
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 1 1 1 0 1 1 1 1 1 1 1 1 1
Profit before tax -5 2 2 8 1 3 3 -2 8 0 4 6 5
Tax % 5.87% 40.0% 34.31% -8.69% 59.52% 15.76% 23.89% -86.83% -3.66% 1,300.0% 16.51% -4.0% 14.96%
Net Profit + -5 1 1 9 0 3 2 0 8 -1 4 7 4
EPS in Rs -1 0 0 1 0 0 0 0 1 0 0 1 1
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 124 132 134 125 150 133 163 197 170 173 196 202 206
Expenses + 129 145 137 137 144 136 165 171 162 167 187 190 191
Operating Profit -4 -13 -3 -12 6 -3 -2 25 8 6 9 12 15
OPM % -3.5% -10.0% -2.1% -9.0% 3.9% -2.5% -0.9% 13.0% 5.0% 3.4% 4.6% 6.0% 7.0%
Other Income + 13 95 -2 25 8 24 40 33 12 10 5 15 9
Interest 10 4 5 3 3 4 3 2 3 6 5 4 4
Depreciation 5 17 4 2 2 3 2 2 3 4 4 4 4
Profit before tax -6 62 -14 8 8 15 33 54 15 7 5 19 15
Tax % 13.0% 22.0% 34.0% 84.0% 48.0% 6.0% 10.0% 13.0% 25.0% 15.0% -2.0% 4.0% —
Net Profit + -7 48 -18 1 4 14 29 47 11 6 5 18 14
EPS in Rs -1 6 -2 0 1 2 4 6 1 1 1 2 2
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves -86 -38 -51 -50 -46 -32 -3 43 54 60 63 82
Borrowings + 46 47 42 43 40 31 28 27 45 46 51 57
Other Liabilities + 132 94 93 128 144 111 108 84 70 67 79 65
Total Liabilities 169 180 160 197 214 186 210 231 246 250 270 280
Fixed Assets + 91 72 72 59 58 57 57 58 85 88 87 89
CWIP 1 9 3 14 24 0 1 12 4 0 0 4
Investments 1 8 5 5 9 18 27 33 32 29 32 32
Other Assets + 76 92 80 119 123 110 125 128 125 133 151 155
Total Assets 169 180 160 197 214 186 210 231 246 250 270 280
Equity Capital 77 77 77 77 77 77 77 77 77 77 77 77

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -8 -75 5 -7 19 -7 -2 11 6 9 -18 13
Cash from Investing Activity + 10 80 -3 18 -9 17 10 5 -17 -5 13 -10
Cash from Financing Activity + -1 -3 -6 -2 -6 -14 -6 -19 9 -3 -2 -2
Net Cash Flow 1 2 -4 8 3 -4 2 -3 -2 1 -6 1
CFO/OP 90 551 -252 -107 453 134 22 60 120 217 -160 107
Free Cash Flow 1 12 1 8 9 -10 7 16 -15 6 -20 7

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 30.78% → 31.36%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 69.23% 69.21% 69.23% 69.22% 68.65% 68.54% 68.18% 68.26% 68.32% 68.29% 68.64% 68.64%
Promoters 30.78% 30.78% 30.78% 30.78% 31.35% 31.35% 31.35% 31.35% 31.35% 31.36% 31.36% 31.36%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.38% 0.38% 0.34% 0.34% 0.0% 0.0%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Ambalal Sarabhai Ent L (this stock) 316 22.2 2.0 12.4%
Lyka Labs Ltd. 310 — 3.31 -10.2%
Nureca Limited 335 77.3 1.86 1.12%
Qms Medical Allied S Ltd 380 35.4 3.65 10.4%
Bilcare Ltd. 232 11.7 1.22 1.39%
Take Limited 229 38.9 7.38 16.5%
Nectar Lifesciences Ltd. 211 — 0.36 -31.3%

Which Mutual Funds Hold Ambalal Sarabhai Ent L?

Frequently Asked Questions about Ambalal Sarabhai Ent L

Community Sentiment

What are other investors saying about Ambalal Sarabhai Ent L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.